Albany, NY -- (SBWire) -- 09/03/2019 --Frontotemporal Dementia Market Insights, Epidemiology and Market Forecast-2028

1. The early-onset Frontotemporal Dementia prevalence and Alzheimer's Disease were the same which was estimated to be 15 per 100,000 in 45- to 64-year-old population.
2. Frontotemporal dementia, a heterogeneous neurodegenerative disorder, is a common cause of young onset dementia. The estimated Frontotemporal Dementia prevalence was 15–22/ per 100,000 and incidence 2.7–4.1 per 100,000.
3. Frontotemporal Dementia represents an estimated 10–20% of all dementia cases.

DelveInsight launched a new report on Frontotemporal Dementia Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Frontotemporal Dementia market report covers a descriptive overview and comprehensive insight of the Frontotemporal Dementia epidemiology and Frontotemporal Dementia market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Frontotemporal Dementia market report provides insights on the current and emerging therapies.
3. Frontotemporal Dementia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Frontotemporal Dementia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Frontotemporal Dementia market.

Request for sample pages

In the current Frontotemporal Dementia market scenario, there is no targeted therapy specifically for the cure, but there are some symptomatic Frontotemporal Dementia treatments which are being given to the patients. The symptomatic Frontotemporal Dementia treatments include the use of antidepressants and antipsychotics and also involve some speech therapy sessions. People experiencing language difficulties may benefit from speech therapy to learn alternate strategies for communication. Frontotemporal Dementia is often misdiagnosed as a psychiatric problem or as Alzheimer's disease, which is also a concern to be observed.
The antidepressants drugs which are preferred are fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, bupropion, and mirtazapine, whereas antipsychotics drugs such as olanzapine, quetiapine, ziprasidone, aripiprazole, risperidone, and paliperidone are mainly used. The above-described medications may help in controlling behavioral problems, overeating, and compulsive behavior.
Even though these therapies are available for the management of Frontotemporal Dementia symptoms, they have some limitations such as high dose of these therapies, which may cause life-threatening adverse effects. So, there is a high unmet need for novel Frontotemporal Dementia therapies that can overcome these limitations. In addition to this, there is no effective therapy for cognitive complaints, which frequently involve executive function, memory, and language.
To redress the current issues, the companies are currently working on novel therapies to meet the needs of the current market. Companies are primarily focused on adapting to the latest technological advancement in drug manufacturing and offering drugs with the reduced side effect for the frontotemporal dementia treatment. Moreover, the research and development in advanced gene therapy, particularly in the fields of neurodegeneration, is offering the manufacturers involved in frontotemporal dementia treatment market, a prime scope for competition.

The launch of the emerging therapies is expected to significantly impact the Frontotemporal Dementia treatment scenario in the upcoming years:-
Drugs covered
1. LMTX
2. Biogen
3. Alector
And many others

The key players in Frontotemporal Dementia market are:
1. TauRx Therapeutics
2. Alector
3. Biogen
And many others
Table of contents

1. Report Introduction
2. Frontotemporal Dementia Market Overview at a Glance
3. Frontotemporal Dementia Disease Background and Overview
4. Frontotemporal Dementia Epidemiology and Patient Population
5. Frontotemporal Dementia Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Frontotemporal Dementia Treatment & Medical Practices
7. Frontotemporal Dementia Emerging Therapies
7.1. Key Cross Competition
7.2. LMTX : TauRx Therapeutics
8. Frontotemporal Dementia Market Size
9. 7MM Frontotemporal Dementia Country-Wise Market Analysis
9.1. United States
9.2. Germany
9.3. France
9.4. United Kingdom
9.5. Spain
9.6. Italy
9.7. Japan
10. Frontotemporal Dementia Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight

PharmDelve- a subscription-based platform by DelveInsight, has business intelligence and market research repository. It is engrained with rich features aiming to revolutionize the way market reports are delivered and manoeuvred. If you want to get more details then click on our link: https://www.pharmdelve.com/ or call now: +1(919)321-6187.